Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANI PHARMACEUTICALS INCANIP · Entity 4638 | Director | August 19, 2026 | August 27, 2026 |
| AbbVie Inc.ABBV · Entity 2800 | EVP, Chief Strategy Officer | May 16, 2022 | May 20, 2022 |
| Aptinyx Inc.APTX · Entity 120922 | Director | May 26, 2022 | May 31, 2022 |
| Neumora Therapeutics, Inc.NMRA · Entity 6115 | Director · President & CEO | February 14, 2024 | February 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANI PHARMACEUTICALS INC
Report date August 19, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,662 |
Reported balance
After 2026-08-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-19 · Grant · Acquired 6,662 · Balance 6,662 F1: Represents a restricted stock award that will vest in three equal annual installments on the first, second and third anniversaries of August 19, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock award that will vest in three equal annual installments on the first, second and third anniversaries of August 19, 2026.
AbbVie Inc.
Report date May 16, 2022 · Filed May 20, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 41,623 |
Last balance in matching sequence
After 2022-05-16 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-05-16 · Exercise / conversion · Acquired 83,960 · Balance 125,583 Row 2 · 2022-05-16 · Sale · Disposed 83,960 · Balance 41,623 |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $54.86 · Expires 2026-02-17 | Direct | 0 |
Reported balance
After 2022-05-16 transaction · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · 2022-05-16 · Exercise / conversion · Disposed 83,960 · Balance 0 F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectIn trust | 53,500 |
Reported balance
Holding disclosure · report date 2022-05-16 · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · Balance 53,500 F1: The reporting person is trustee of a trust established for the benefit of his children. The reporting person disclaims beneficial ownership of all securities held by the trust. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectProfit sharing trust | 3,638 |
Reported balance
Holding disclosure · report date 2022-05-16 · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · Balance 3,638 F2: Balance in AbbVie Savings program as of May 18, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is trustee of a trust established for the benefit of his children. The reporting person disclaims beneficial ownership of all securities held by the trust.
F2: Balance in AbbVie Savings program as of May 18, 2022.
F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.
Aptinyx Inc.
Report date May 26, 2022 · Filed May 31, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2032-05-25 | Direct | 40,000 |
Reported balance
After 2022-05-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-26 · Grant · Acquired 40,000 · Balance 40,000 F1: This option vests in ratable monthly installments over one year from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in ratable monthly installments over one year from the date of grant.
Neumora Therapeutics, Inc.
Report date February 14, 2024 · Filed February 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 462,345 |
Reported balance
After 2024-02-14 transaction · row 1
1 source rowRow 1 · 2024-02-14 · Grant · Acquired 80,000 · Balance 462,345 F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.07 · Expires 2034-02-13 | Direct | 160,000 |
Reported balance
After 2024-02-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-14 · Grant · Acquired 160,000 · Balance 160,000 F4: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 15,000 |
Reported balance
Holding disclosure · report date 2024-02-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 15,000 F2: Shares held by HG4KYC TRUST, of which Reporting Person is trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 127,448 |
Reported balance
Holding disclosure · report date 2024-02-14 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 127,448 F3: Shares held by Lu Leng Felicia Chua Descendants 2012 Irrevocable Trust, of which Reporting Person is trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.
F2: Shares held by HG4KYC TRUST, of which Reporting Person is trustee.
F3: Shares held by Lu Leng Felicia Chua Descendants 2012 Irrevocable Trust, of which Reporting Person is trustee.
F4: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACELYRIN, Inc.
Report date May 21, 2025 · Filed May 23, 2025
Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 1
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-21 · Disposition to issuer · Disposed 92,158 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F2: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.43 · Expires 2033-03-22 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-21 · Disposition to issuer · Disposed 155,450 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F4: 1/48 of the shares subject to the option vested on April 17, 2023 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.
F2: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.
F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.
F4: 1/48 of the shares subject to the option vested on April 17, 2023 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 27, 2026 20:21 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 6,662 | $0.00 | $0.00 |
DisclosureSEC source: 0001659625-26-000011 · wk-form4_1787862115.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,662 F1 · balance_after: Represents a restricted stock award that will vest in three equal annual installments on the first, second and third anniversaries of August 19, 2026. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:07 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 155,450 | Not disclosed Strike: $7.43 | Not disclosed |
DisclosureSEC source: 0001962918-25-000058 · wk-form4_1748030845.xml · derivative · entry 3 Gosebruch Henry O · CIK 0001659625 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 155,450 shares Expires 2033-03-22 F3 · price: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F4 · derivative.exercise_date: 1/48 of the shares subject to the option vested on April 17, 2023 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:07 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 92,158 | Not disclosed Strike: $4.46 | Not disclosed |
DisclosureSEC source: 0001962918-25-000058 · wk-form4_1748030845.xml · derivative · entry 2 Gosebruch Henry O · CIK 0001659625 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 92,158 shares Expires 2034-06-06 F3 · price: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F2 · derivative.exercise_date: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:07 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Disposition to issuerCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001962918-25-000058 · wk-form4_1748030845.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 23:11 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantDirector Stock Option (right to buy) · Derivative | 92,158 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001962918-24-000091 · wk-form4_1718147510.xml · derivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,158 Underlying: Common Stock · 92,158 shares Expires 2034-06-06 F1 · derivative.exercise_date: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:15 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $18.07 | $0.00 |
DisclosureSEC source: 0001610717-24-000065 · form4.xml · derivative · entry 4 Gosebruch Henry O · CIK 0001659625 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2034-02-13 F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:15 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000065 · form4.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 462,345 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 01:47 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | PurchaseCommon Stock | 15,000 | $12.62 | $189,370.50 |
DisclosureSEC source: 0001610717-23-000290 · form4.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 15,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $12.465 to $12.65, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. F2 · ownership.nature: Shares held by HG4KYC TRUST, of which Reporting Person is trustee. Read SEC document |
| May 09, 2023 Filed May 12, 2023 01:06 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherDirector Stock Option (right to buy) · Derivative | 155,450 | $0.00 Strike: $7.43 | $0.00 |
DisclosureSEC source: 0001209191-23-028878 · doc4.xml · derivative · entry 3 Gosebruch Henry O · CIK 0001659625 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,450 Underlying: Common Stock · 155,450 shares Expires 2033-03-22 F2 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F3 · derivative.exercise_date: 1/48 of the shares subject to the option vested on April 17, 2023 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document |
| May 09, 2023 Filed May 12, 2023 01:06 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherDirector Stock Option (right to buy) · Derivative | 155,450 | $0.00 Strike: $7.43 | $0.00 |
DisclosureSEC source: 0001209191-23-028878 · doc4.xml · derivative · entry 2 Gosebruch Henry O · CIK 0001659625 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 155,450 shares Expires 2033-03-22 F2 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F3 · derivative.exercise_date: 1/48 of the shares subject to the option vested on April 17, 2023 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document |
| May 09, 2023 Filed May 12, 2023 01:06 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | PurchaseCommon Stock | 50,000 | $18.00 | $900,000.00 |
DisclosureSEC source: 0001209191-23-028878 · doc4.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the "IPO"). Read SEC document |
| May 26, 2022 Filed May 31, 2022 16:31 UTC | Aptinyx Inc. APTX · Entity 120922 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001415889-22-005908 · form4-05312022_040541.xml · derivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: This option vests in ratable monthly installments over one year from the date of grant. Read SEC document |
| May 16, 2022 Filed May 18, 2022 21:12 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 83,960 | $54.86 Strike: $54.86 | $4,606,045.60 |
DisclosureSEC source: 0001179110-22-003076 · edgar.xml · derivative · entry 5 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,960 shares Expires 2026-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 16, 2022 Filed May 18, 2022 21:12 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 83,960 | $155.00 | $13,013,800.00 |
DisclosureSEC source: 0001179110-22-003076 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,623 Read SEC document |
| May 16, 2022 Filed May 18, 2022 21:12 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 83,960 | $54.86 | $4,606,045.60 |
DisclosureSEC source: 0001179110-22-003076 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2022 Filed May 20, 2022 21:03 UTC Amendment | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 83,960 | $54.86 Strike: $54.86 | $4,606,045.60 |
DisclosureSEC source: 0001179110-22-003108 · edgar.xml · derivative · entry 5 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,960 shares Expires 2026-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 16, 2022 Filed May 20, 2022 21:03 UTC Amendment | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 83,960 | $155.00 | $13,013,800.00 |
DisclosureSEC source: 0001179110-22-003108 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,623 Read SEC document |
| May 16, 2022 Filed May 20, 2022 21:03 UTC Amendment | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 83,960 | $54.86 | $4,606,045.60 |
DisclosureSEC source: 0001179110-22-003108 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:14 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 1,101 | $149.14 | $164,207.65 |
DisclosureSEC source: 0001179110-22-001841 · edgar.xml · nonDerivative · entry 4 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,623 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.95 to $149.40 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:14 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 8,303 | $148.62 | $1,234,011.79 |
DisclosureSEC source: 0001179110-22-001841 · edgar.xml · nonDerivative · entry 3 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,724 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.94 to $148.93 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:14 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 5,596 | $147.54 | $825,616.49 |
DisclosureSEC source: 0001179110-22-001841 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,027 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.89 to $147.88 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 22:03 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 100 | $149.38 | $14,938.10 |
DisclosureSEC source: 0001179110-22-001923 · edgar.xml · nonDerivative · entry 4 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,623 F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.38 to $149.39 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 22:03 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 4,000 | $148.71 | $594,824.00 |
DisclosureSEC source: 0001179110-22-001923 · edgar.xml · nonDerivative · entry 3 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,723 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.37 to $148.96 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 22:03 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 5,167 | $147.60 | $762,656.95 |
DisclosureSEC source: 0001179110-22-001923 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,723 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.35 to $148.11 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 22:03 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 15,733 | $146.81 | $2,309,769.60 |
DisclosureSEC source: 0001179110-22-001923 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,890 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.31 to $147.30 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed May 20, 2022 21:00 UTC Amendment | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 100 | $149.38 | $14,938.10 |
DisclosureSEC source: 0001179110-22-003107 · edgar.xml · nonDerivative · entry 5 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Indirect · In trust Disclosed balance after: 53,500 F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.38 to $149.39 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · balance_after: The reporting person is trustee of a trust established for the benefit of his children. The reporting person disclaims beneficial ownership of all securities held by the trust. F7 · balance_after: Due to an administrative error, the original Form 4 filed on March 2, 2022 incorrectly reported that the 25,000 securities sold on March 1, 2022 were securities directly owned by the reporting person. Instead, the securities sold on that date were securities indirectly owned in trust by the reporting person. This amended Form 4 corrects that error. Read SEC document |
| March 01, 2022 Filed May 20, 2022 21:00 UTC Amendment | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 4,000 | $148.71 | $594,824.00 |
DisclosureSEC source: 0001179110-22-003107 · edgar.xml · nonDerivative · entry 4 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Indirect · In trust Disclosed balance after: 53,600 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.37 to $148.96 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed May 20, 2022 21:00 UTC Amendment | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 5,167 | $147.60 | $762,656.95 |
DisclosureSEC source: 0001179110-22-003107 · edgar.xml · nonDerivative · entry 3 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Indirect · In trust Disclosed balance after: 57,600 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.35 to $148.11 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed May 20, 2022 21:00 UTC Amendment | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 15,733 | $146.81 | $2,309,769.60 |
DisclosureSEC source: 0001179110-22-003107 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Indirect · In trust Disclosed balance after: 62,767 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.31 to $147.30 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:14 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 30,156 | $149.54 | $4,509,528.24 |
DisclosureSEC source: 0001179110-22-001841 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,623 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:39 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 30,647 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001513 · edgar.xml · derivative · entry 7 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,647 Underlying: Common Stock · 30,647 shares Expires 2032-02-16 F7 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,216 on February 17, 2023, 10,216 on February 17, 2024, and 10,215 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:39 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 8,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001513 · edgar.xml · nonDerivative · entry 4 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,779 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:39 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 14,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001513 · edgar.xml · nonDerivative · entry 3 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,078 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:39 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 7,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001513 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,356 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:39 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 36,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001513 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,384 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| September 07, 2021 Filed Sep 10, 2021 21:01 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-008720 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Indirect · In trust Disclosed balance after: 78,500 F1 · balance_after: The reporting person is trustee of a trust established for the benefit of his children. The reporting person disclaims beneficial ownership of all securities held by the trust. Read SEC document |
| September 07, 2021 Filed Sep 10, 2021 21:01 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-008720 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,711 Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 16:36 UTC | Aptinyx Inc. APTX · Entity 120922 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001415889-21-002740 · form4-06012021_010656.xml · derivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-05-26 F1 · derivative.exercise_date: This option vests in ratable monthly installments over one year from the date of grant. Read SEC document |
| February 28, 2021 Filed Mar 3, 2021 01:34 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 22,833 | $107.74 | $2,460,027.42 |
DisclosureSEC source: 0001179110-21-002611 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,711 Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:25 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption(right to buy) · Derivative | 49,068 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002053 · edgar.xml · derivative · entry 7 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,068 Underlying: Common Stock · 49,068 shares Expires 2031-02-17 F7 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,356 on February 18, 2022, 16,356 on February 18, 2023, and 16,356 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:25 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 14,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002053 · edgar.xml · nonDerivative · entry 4 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,544 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:25 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 7,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002053 · edgar.xml · nonDerivative · entry 3 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,820 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:25 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 6,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002053 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,848 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:25 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 22,287 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002053 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,293 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 16:31 UTC | Aptinyx Inc. APTX · Entity 120922 | GrantStock Option (Right to Buy) · Derivative | 5,339 | $2.22 Strike: $3.46 | $11,873.94 |
DisclosureSEC source: 0001415889-21-000088 · form4-01052021_040107.xml · derivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,339 Underlying: Common Stock · 5,339 shares Expires 2030-12-30 F1 · shares: The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 22:34 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par shar | 33,100 | $99.49 | $3,293,119.00 |
DisclosureSEC source: 0001179110-20-011342 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,006 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.00 to $99.88, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 22:34 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par share | 6,900 | $98.83 | $681,927.00 |
DisclosureSEC source: 0001179110-20-011342 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,106 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.65 to $98.98, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 15:05 UTC | Aptinyx Inc. APTX · Entity 120922 | GrantStock Option (Right to Buy) · Derivative | 5,490 | $2.16 Strike: $3.38 | $11,874.87 |
DisclosureSEC source: 0001415889-20-002399 · form4-10022020_031006.xml · derivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,490 Underlying: Common Stock · 5,490 shares Expires 2030-09-29 F1 · shares: The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 16:06 UTC | Aptinyx Inc. APTX · Entity 120922 | GrantStock Option (Right to Buy) · Derivative | 4,051 | $2.68 Strike: $4.17 | $10,844.53 |
DisclosureSEC source: 0001415889-20-001796 · form4-07022020_040758.xml · derivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,051 Underlying: Common Stock · 4,051 shares Expires 2030-06-29 F1 · shares: The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| May 20, 2020 Filed May 22, 2020 16:11 UTC | Aptinyx Inc. APTX · Entity 120922 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001104659-20-065362 · a4.xml · derivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-05-19 F1 · derivative.exercise_date: This option vests in ratable monthly installments over one year from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.